T Acute Lymphoblastic Leukemia Clinical Trial
Official title:
Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL
NCT number | NCT04582487 |
Other study ID # | ALL2720 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | May 19, 2021 |
Est. completion date | May 2024 |
This is a biological study for R/R T-ALL/LBL or ETP-ALL patients. Bone marrow and/or peripheral blood samples will be subjected to genomic, DSRP profiling and phosphoproteomic screening to identify novel potential therapeutic approach and thus, eligibility for treatment based on molecular and DSRP data. As soon as genomic and DSRP profiling are made available, local Investigator can submit to local ethic committee a request for clinical use of identified compound.
Status | Recruiting |
Enrollment | 32 |
Est. completion date | May 2024 |
Est. primary completion date | May 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients to be enrolled in this study must have T-cell ALL or T-cell lymphoblastic lymphoma (LL) in the first relapse or must have failed primary induction chemotherapy (i.e., never attained a complete remission following an initial course of standard therapy for T-ALL/LBL or have a diagnosis of ETP-ALL [T-ALL with the following phenotype: Negative: CD1a-, CD8-, CD4-, CD5 (less than 75% of blasts); CD13+, CD33+, CD34+, CD117+, HLA-DR+, CD11b+, and/or CD65+ -in at least 25% of lymphoblasts - Ages Eligible for Study: over 18 years - Patients with T-ALL/LBL must have greater than 5% blasts in the bone marrow with or without extramedullary disease - Patients with T-ALL/LBL must have recurrent disease, documented by clinical or radiographic criteria, as well as histologic verification of the malignancy at original diagnosis - Patients may have CNS 1 (WBC count in CSF <5 and having no blasts) or CNS 2 (WBC count in CSF <5 and having blasts) disease but not CNS 3 (WBC count in CSF =5 and having blasts) - ECOG 0-2 or Karnofsky = 50% - Patients may be enrolled on study regardless of the timing of prior Intrathecal therapy; however, they may not begin treatment on this protocol until a minimum of 7 days has elapsed since prior intrathecal therapy - Adequate renal function defined as serum creatinine = 1.5x upper limit of normal (ULN) for age. If the serum creatinine is above these values, the calculated creatinine clearance or radioisotope GFR must be = 70 mL/min/1.73m2 - Total bilirubin = 1.5x ULN for age. If the total bilirubin is elevated, patient will still be eligible if the conjugated (direct) serum bilirubin = ULN for age - ALT = 5x ULN of normal for age - Adequate cardiac function defined as shortening fraction of = 27% by echocardiogram or ejection fraction = 45% by gated radionuclide study - No evidence of dyspnea at rest - No exercise intolerance - A pulse oximetry = 94% at sea level (= 90% at altitude = 5000 feet) if there is clinical indication for determination - Patients must be capable of understanding the investigational nature, potential risks and benefits of the study. All patients must sign a written informed consent Exclusion Criteria: - Significant organ compromise that will increase risk of toxicity or mortality - Active serious infection not controlled by oral or intravenous antibiotics - Active secondary malignancy other than skin cancer (e.g., basal cell carcinoma or squamous cell carcinoma) that in the investigator's opinion will shorten survival to less than 1 year - Known hepatitis B or C infection, or known seropositivity for human immunodeficiency virus (HIV) - Active grade III-V cardiac failure as defined by the New York Heart Association Criteria - Patients with a cardiac ejection fraction (as measured by either multigated acquisition [MUGA] or echocardiogram) < 40% |
Country | Name | City | State |
---|---|---|---|
Italy | Aou Ospedali Riuniti "Umberto I - G.M. Lancisi - G. Salesi"- Ancona - Sod Clinica Ematologica | Ancona | |
Italy | Asst Papa Giovanni Xxiii - Ospedale Di Bergamo - Sc Ematologia | Bergamo | |
Italy | Aou Di Bologna - Policlinico S. Orsola-Malpighi - Uoc Ematologia | Bologna | |
Italy | Asst Degli Spedali Civili Di Brescia - Uo Ematologia | Brescia | |
Italy | Asl Lecce, Ospedale 'V. Fazzi' - Uo Ematologia | Lecce | |
Italy | Aulss 3 Serenissima, Ospedale Dell'Angelo - Mestre - Uo Ematologia | Mestre | |
Italy | Ematologia ed Immunologia Clinica | Perugia | |
Italy | Fondazione Policlinico Universitario Agostino Gemelli Irccs - Roma - Area Ematologica | Roma | |
Italy | Aou Senese - Uoc Ematologia E Trapianti | Siena | |
Italy | Aulss 8 Berica - Ospedale Di Vicenza - Uoc Ematologia | Vicenza |
Lead Sponsor | Collaborator |
---|---|
Gruppo Italiano Malattie EMatologiche dell'Adulto |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Drug sensitivity profile | Frequencies of alternative therapies identified for T-ALL patients | baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02484430 -
Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia
|
Phase 2 | |
Recruiting |
NCT04620655 -
RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL
|
N/A | |
Terminated |
NCT03519984 -
EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia
|
Phase 1 | |
Recruiting |
NCT04128501 -
Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting
|
Phase 2 | |
Recruiting |
NCT00501826 -
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
|
Phase 2 | |
Withdrawn |
NCT02538926 -
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT00408005 -
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
|
Phase 3 | |
Terminated |
NCT02767934 -
Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia
|
Phase 2 | |
Withdrawn |
NCT06210750 -
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
|
Phase 2 | |
Recruiting |
NCT03007147 -
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
|
Phase 3 | |
Recruiting |
NCT05602194 -
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
|
Phase 3 | |
Recruiting |
NCT03504644 -
Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 |